

Publikationsliste 2014

Originalarbeiten

1. Aalen O, Roysland K, Gran J, Kouyos R, Lange T. Can we believe the DAGs? A comment on the relationship between causal DAGs and mechanisms. *Stat Methods Med Res.* 2014.
2. Abdelhady W, Bayer AS, Seidl K, Moormeier DE, Bayles KW, Cheung A, Yeaman MR, Xiong YQ. Impact of vancomycin on sarA-mediated biofilm formation: role in persistent endovascular infections due to methicillin-resistant *Staphylococcus aureus*. *J Infect Dis.* 2014;209(8):1231-40.
3. Abdel-Mohsen M, Deng X, Danesh A, Liegler T, Jacobs ES, Rauch A, Ledergerber B, Norris PJ, Gunthard HF, Wong JK, Pillai SK. Role of microRNA modulation in the interferon-alpha/ribavirin suppression of HIV-1 in vivo. *PLoS One.* 2014;9(10):e109220.
4. Abdel-Mohsen M, Deng X, Liegler T, Guatelli JC, Salama MS, Ghanem Hel D, Rauch A, Ledergerber B, Deeks SG, Gunthard HF, Wong JK, Pillai SK. Effects of alpha interferon treatment on intrinsic anti-HIV-1 immunity in vivo. *J Virol.* 2014;88(1):763-7.
5. Abel Zur Wiesch P, Kouyos R, Abel S, Viechtbauer W, Bonhoeffer S. Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. *PLoS Pathog.* 2014;10(6):e1004225.
6. Achermann Y, Stasch P, Preiss S, Lucke K, Vogt M. Characteristics and treatment outcomes of 69 cases with early prosthetic joint infections of the hip and knee *Infection.* 2014;42(3):511-9.
7. Althaus CL, Joos B, Perelson AS, Gunthard HF. Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. *PLoS Comput Biol.* 2014;10(10):e1003871.
8. Andreoni F, Ogawa T, Ogawa M, Madon J, Uchiyama S, Schuepbach RA, Zinkernagel AS. The IL-8 protease SpyCEP is detrimental for Group A *Streptococcus* host-cells interaction and biofilm formation. *Front Microbiol.* 2014;5:339.
9. Arab-Alameddine M, Lubomirov R, Fayet-Mello A, Aouri M, Rotger M, Buclin T, Widmer N, Gatri M, Ledergerber B, Rentsch K, Cavassini M, Panchaud A, Guidi M, Telenti A, Decosterd LA, Csajka C, SwissHIVCohortStudy. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. *J Antimicrob Chemother.* 2014;69(9):2489-98.
10. Avila D, Keiser O, Egger M, Kouyos R, Boni J, Yerly S, Klimkait T, Vernazza PL, Aubert V, Rauch A, Bonhoeffer S, Gunthard HF, Stadler T, Spycher BD, SwissHIVCohortStudy. Social meets molecular: Combining phylogenetic and latent class analyses to understand HIV-1 transmission in Switzerland. *Am J Epidemiol.* 2014;179(12):1514-25.

11. Bastidas S, Graw F, Smith MZ, Kuster H, Gunthard HF, Oxenius A. CD8+ T cells are activated in an antigen-independent manner in HIV-infected individuals. *J Immunol.* 2014;192(4):1732-44.
12. Bibert S, Wojtowicz A, Taffe P, Manuel O, Bernasconi E, Furrer H, Gunthard HF, Hoffmann M, Kaiser L, Osthoff M, Cavassini M, Bochud PY, SwissHIVCohortStudy. The IFNL3/4 DeltaG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. *AIDS.* 2014;28(13):1885-9.
13. Boillat-Blanco N, Darling KE, Schoni-Affolter F, Vuichard D, Rougemont M, Fulchini R, Bernasconi E, Aouri M, Clerc O, Furrer H, Gunthard HF, Cavassini M, SwissHIVCohortStudy. Virological outcome and management of persistent lowlevel viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. *Antivir Ther.* 2014.
14. Brandenburg OF, Rusert P, Magnus C, Weber J, Boni J, Gunthard HF, Regoes RR, Trkola A. Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain inverted question marks exceptional capacity for sequence variation. *Retrovirology.* 2014;11(1):75.
15. Braun DL, Kouyos R, Oberle C, Grube C, Joos B, Fellay J, McLaren PJ, Kuster H, Gunthard HF. A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. *PLoS One.* 2014;9(12):e114111.
16. Braun DL, Rauch A, Durisch N, Eberhard N, Anagnostopoulos A, Ledergerber B, Metzner KJ, Boni J, Weber R, Fehr J. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. *HIV Med.* 2014;15(10):625-30.
17. Braun J, Held L, Ledergerber B, SwissHIVCohortStudy. Accounting for baseline differences and measurement error in the analysis of change over time. *Stat Med.* 2014;33(1):2-16.
18. Bucheli E, Kralidis G, Boggian K, Cusini A, Garzoni C, Manuel O, Meylan PR, Mueller NJ, Khanna N, van Delden C, Berger C, Koller MT, Weisser M, SwissTransplantCohortStudy. Impact of enterococcal colonization and infection in solid organ transplantation recipients from the Swiss transplant cohort study. *Transpl Infect Dis.* 2014;16(1):26-36.
19. Buchler AC, Rampini SK, Stelling S, Ledergerber B, Peter S, Schweiger A, Ruedf, C, Zbinden R, Speck RF. Antibiotic susceptibility of *Clostridium difficile* is similar worldwide over two decades despite widespread use of broad-spectrum antibiotics: an analysis done at the University Hospital of Zurich. *BMC Infect Dis.* 2014;14(1):607.
20. Buetikofer S, Wandeler G, Kouyos R, Weber R, Ledergerber B. Prevalence and risk factors of late presentation for HIV diagnosis and care in a tertiary referral centre in Switzerland. *Swiss Med Wkly.* 2014;144:w13961.

21. Clack L, Kuster SP, Giger H, Giuliani F, Sax H. Low-hanging fruit for human factors design in infection prevention--still too high to reach? *Am J Infect Control*. 2014;42(6):679-81.
22. Clack L, Schmutz J, Manser T, Sax H. Infectious risk moments: a novel, human factors-informed approach to infection prevention. *Infect Control Hosp Epidemiol*. 2014;35(8):1051-5.
23. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S, Team INGS. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet*. 2014;383(9936):2222-31.
24. Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Daumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Gunthard HF, Brun-Vezinet F, Paredes R, Metzner KJ, on behalf of the CMHIVVWG. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European casecontrol study using centralized ultrasensitive 454 pyrosequencing. *J Antimicrob Chemother*. 2014.
25. Drescher SM, von Wyl V, Yang WL, Boni J, Yerly S, Shah C, Aubert V, Klimkait T, Taffe P, Furrer H, Battegay M, Ambrosioni J, Cavassini M, Bernasconi E, Vernazza PL, Ledergerber B, Gunthard HF, Kouyos RD, wissHIVCohortStudy. Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. *Clin Infect Dis*. 2014;58(2):285-94.
26. Fitzmaurice K, Hurst J, Dring M, Rauch A, McLaren PJ, Gunthard HF, Gardiner C, Klenerman P, Irish HCVRC, SwissHIVCohortStudy. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. *Gut*. 2014.
27. Giallonardo FD, Topfer A, Rey M, Prabhakaran S, Duport Y, Leemann C, Schmutz S, Campbell NK, Joos B, Lecca MR, Patrignani A, Daumer M, Beisel C, Rusert P, Trkola A, Gunthard HF, Roth V, Beerwinkel N, Metzner KJ. Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. *Nucleic Acids Res*. 2014;42(14):e115.
28. Glatz M, Juricevic N, Altwegg M, Bruisten S, Komericki P, Lautenschlager S, Weber R, Bosshard PP. A multicenter prospective trial to assess a new real-time polymerase chain reaction for detection of *Treponema pallidum*, herpes simplex- 1/2 and *Haemophilus ducreyi* in genital, anal and oropharyngeal ulcers. *Clinical Microbiology and Infection*. 2014;20(12):O1020-O7.
29. Glatz M, Mullegger RR, Maurer F, Fingerle V, Achermann Y, Wilske B, Bloemberg GV. Detection of *Candidatus Neoehrlichia mikurensis*, *Borrelia burgdorferi sensu lato* genospecies and *Anaplasma phagocytophilum* in a tick population from Austria. *Ticks Tick Borne Dis*. 2014;5(2):139-44.

30. Gonzalez A, Schmitter K, Hirsch HH, Garzoni C, van Delden C, Boggian K, Mueller NJ, Berger C, Villard J, Manuel O, Meylan P, Stern M, Hess C, SwissTransplantCohortStudy. KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients. *Genes Immun*. 2014;15(7):495-9.
31. Gonzalez DJ, Vuong L, Gonzalez IS, Keller N, McGrosso D, Hwang JH, Hung J, Zinkernagel A, Dixon JE, Dorrestein PC, Nizet V. Phenol soluble modulins (PSM) variants of community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) captured using mass spectrometry-based molecular networking. *Mol Cell Proteomics*. 2014;13(5):1262-72.
32. Grankvist A, Andersson PO, Mattsson M, Sender M, Vaht K, Hoper L, Sakiniene E, Trysberg E, Stenson M, Fehr J, Pekova S, Bogdan C, Bloemberg G, Wenneras C. Infections with the tick-borne bacterium "*Candidatus Neoehrlichia mikurensis*" mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases. *Clin Infect Dis*. 2014;58(12):1716-22.
33. Guennewig B, Roos M, Dogar AM, Gebert LF, Zagalak JA, Vongrad V, Metzner KJ, Hall J. Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF- α . *RNA*. 2014;20(1):61-75.
34. Haas F, Yamauchi K, Murat M, Bernasconi M, Yamanaka N, Speck RF, Nadal D. Activation of NF- κ B via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation. *J Virol*. 2014;88(17):10002-12.
35. Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, Cavassini M, Bernasconi E, Marzolini C, Tarr PE, SwissHIVCohortStudy. Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. *Open Forum Infectious Diseases*. 2014;1(2).
36. Hasse B, Walker AS, Fehr J, Furrer H, Hoffmann M, Battegay M, Calmy A, Fellay J, Di Benedetto C, Weber R, Ledergerber B, SwissHIVCohortStudy. Cotrimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. *Antimicrob Agents Chemother*. 2014;58(4):2363-8.
37. Hassig A, Roos M, Etter A, Bossart W, Muller N, Schiesser M, Wuthrich RP, Fehr T. Association of BK viremia with human leukocyte antigen mismatches and acute rejection, but not with type of calcineurin inhibitor. *Transpl Infect Dis*. 2014;16(1):44-54.
38. Hernandez D, Seidl K, Corvaglia AR, Bayer AS, Xiong YQ, Francois P. Genome Sequences of Sequence Type 45 (ST45) Persistent Methicillin-Resistant *Staphylococcus aureus* (MRSA) Bacteremia Strain 300-169 and ST45 Resolving MRSA Bacteremia Strain 301-188. *Genome Announc*. 2014;2(2).
39. Klein MB, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan DH, Walmsley S, Gill J, Cooper C, Scherrer AU, Mocroft A, Hogg RS, Smaill F, Canadian-European Clade C. The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to

antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. *CMAJ Open*. 2014;2(4):E318-29.

40. Kohler I, Scherrer AU, Zagordi O, Bianchi M, Wyrzucki A, Steck M, Ledergerber B, Gunthard HF, Hangartner L. Prevalence and predictors for homo- and heterosubtypic antibodies against influenza A virus. *Clin Infect Dis*. 2014;59(10):1386-93.
41. Kouyos RD, Metcalf CJ, Birger R, Klein EY, Abel zur Wiesch P, Ankomah P, Arinaminpathy N, Bogich TL, Bonhoeffer S, Brower C, Chi-Johnston G, Cohen T, Day T, Greenhouse B, Huijben S, Metlay J, Mideo N, Pollitt LC, Read AF, Smith DL, Standley C, Wale N, Grenfell B. The path of least resistance: aggressive or moderate treatment? *Proc Biol Sci*. 2014;281(1794):20140566.
42. Kouyos RD, Rauch A, Boni J, Yerly S, Shah C, Aubert V, Klimkait T, Kovari H, Calmy A, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Gunthard HF, SwissHIVCohortStudy. Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. *Int J Epidemiol*. 2014;43(3):887-96.
43. Kouyos RD, Rauch A, Braun DL, Yang WL, Boni J, Yerly S, Klimkait T, Aubert V, Shah C, Kovari H, Calmy A, Cavassini M, Battegay M, Vernazza PL, Bernasconi E, Ledergerber B, Gunthard HF, SwissHIVCohortStudy. Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. *J Infect Dis*. 2014;210(10):1555-61.
44. Kuster SP, Rudnick W, Shigayeva A, Green K, Baqi M, Gold WL, Lovinsky R, Muller MP, Powis JE, Rau N, Simor AE, Walmsley SL, Low DE, McGeer A, Toronto Invasive Bacterial Diseases N. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. *Clin Infect Dis*. 2014;59(7):944-52.
45. Landelle C, Iten A, Uckay I, Sax H, Camus V, Cohen G, Renzi G, Schrenzel J, Pittet D, Perrier A, Harbarth S. Does colonization with methicillin-susceptible *Staphylococcus aureus* protect against nosocomial acquisition of methicillin-resistant *S. aureus*? *Infect Control Hosp Epidemiol*. 2014;35(5):527-33.
46. Lemmenmeier E, Kohler P, Bruderer T, Goldenberger D, Kleger GR, Schlegel M. First documented outbreak of KPC-2-producing *Klebsiella pneumoniae* in Switzerland: infection control measures and clinical management. *Infection*. 2014;42(3):529-34.
47. Lesurtel M, Raptis DA, Melloul E, Schlegel A, Oberkofler C, El-Badry AM, Weber A, Mueller N, Dutkowski P, Clavien PA. Low platelet counts after liver transplantation predict early posttransplant survival: the 60-5 criterion. *Liver Transpl*. 2014;20(2):147-55.
48. Leventhal GE, Gunthard HF, Bonhoeffer S, Stadler T. Using an epidemiological model for phylogenetic inference reveals density dependence in HIV transmission. *Mol Biol Evol*. 2014;31(1):6-17.

49. Manuel O, Wojtowicz A, Bibert S, Mueller NJ, van Delden C, Hirsch HH, Steiger J, Stern M, Egli A, Garzoni C, Binet I, Weisser M, Berger C, Cusini A, Meylan P, Pascual M, Bochud PY, SwissTransplantCohortStudy. Influence of IFNL3/4 Polymorphisms on the Incidence of Cytomegalovirus Infection After Solid-Organ Transplantation. *J Infect Dis*. 2014.
50. Matt U, Sharif O, Martins R, Knapp S. Accumulating evidence for a role of oxidized phospholipids in infectious diseases. *Cell Mol Life Sci*. 2014.
51. Maurer F, Castelberg C, von Braun A, Wolfensberger A, Bloemberg G, Bottger E, Somoskovi A. Postsurgical wound infections due to rapidly growing mycobacteria in Swiss medical tourists following cosmetic surgery in Latin America between 2012 and 2014. *Euro Surveill*. 2014;19(37).
52. Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, Fadel SA, Tran D, Fernandez E, Bhatnagar N, Loeb M. Populations at risk for severe or complicated Avian Influenza H5N1: a systematic review and meta-analysis. *PLoS One*. 2014;9(3):e89697.
53. Metzner KJ, Scherrer AU, von Wyl V, Boni J, Yerly S, Klimkait T, Aubert V, Furrer H, Hirsch HH, Vernazza PL, Cavassini M, Calmy A, Bernasconi E, Weber R, Gunthard HF, SwissHIVCohortStudy. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. *AIDS*. 2014;28(15):2231-9.
54. Miro JM, Aguero F, Duclos-Vallee JC, Mueller NJ, Grossi P, Moreno A, Hosts ESGoliC. Infections in solid organ transplant HIV-infected patients. *Clin Microbiol Infect*. 2014;20 Suppl 7:119-30.
55. Moradigaravand D, Kouyos R, Hinkley T, Haddad M, Petropoulos CJ, Engelstadter J, Bonhoeffer S. Recombination accelerates adaptation on a large-scale empirical fitness landscape in HIV-1. *PLoS Genet*. 2014;10(6):e1004439.
56. Myburgh R, Cherpin O, Schlaepfer E, Rehrauer H, Speck RF, Krause KH, Salmon P. Optimization of Critical Hairpin Features Allows miRNA-based Gene Knockdown Upon Single-copy Transduction. *Mol Ther Nucleic Acids*. 2014;3:e207.
57. Oesch Nemeth G, Nemeth J, Altpeter E, Ritz N. Epidemiology of childhood tuberculosis in Switzerland between 1996 and 2011. *Eur J Pediatr*. 2014;173(4):457-62.
58. Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Muhlethaler K, Pfyffer G, Ruef C, Fehr J, Zbinden R, Calandra T, Bille J. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. *Clin Microbiol Infect*. 2014;20(7):698-705.
59. Osterhoff G, Spirig J, Klasen J, Kuster SP, Zinkernagel AS, Sax H, Min K. Perforation and bacterial contamination of microscope covers in lumbar spinal

- decompressive surgery. *Med Princ Pract.* 2014;23(4):302-6. 60. Rasi M, Kunzler-Heule P, Schmid P, Semela D, Bruggmann P, Fehr J, Saxer S, Nicca D. "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis. *BMC Infect Dis.* 2014;14:507.
61. Regoes RR, McLaren PJ, Battegay M, Bernasconi E, Calmy A, Gunthard HF, Hoffmann M, Rauch A, Telenti A, Fellay J, SwissHIVCohortStudy. Disentangling human tolerance and resistance against HIV. *PLoS Biol.* 2014;12(9):e1001951.
 62. Rohrbach J, Stickel F, Schmid P, Thormann W, Kovari H, Scherrer A, Gunthard HF, Vuichard D, Cavassini M, Ambrosioni J, Bernasconi E, Furrer H, Rauch A, SwissHIVCohortStudy. Changes in biomarkers of liver disease during successful combination antiretroviral therapy in HIV-HCV-coinfected individuals. *Antivir Ther.* 2014;19(2):149-59.
 63. Schanz M, Liechti T, Zagordi O, Miho E, Reddy ST, Gunthard HF, Trkola A, Huber M. High-throughput sequencing of human immunoglobulin variable regions with subtype identification. *PLoS One.* 2014;9(11):e111726.
 64. Schilcher K, Andreoni F, Uchiyama S, Ogawa T, Schuepbach RA, Zinkernagel AS. Increased neutrophil extracellular trap-mediated *Staphylococcus aureus* clearance through inhibition of nuclease activity by clindamycin and immunoglobulin. *J Infect Dis.* 2014;210(3):473-82.
 65. Schlaepfer E, Rochat MA, Duo L, Speck RF. Triggering TLR2, -3, -4, -5, and -8 reinforces the restrictive nature of M1- and M2-polarized macrophages to HIV. *J Virol.* 2014;88(17):9769-81.
 66. Schuurmans MM, Isenring BD, Jungo C, Boeni J, Mueller NJ, Kohler M, Benden C. Clinical features and outcomes of influenza infections in lung transplant recipients: a single-season cohort study. *Transpl Infect Dis.* 2014;16(3):430-9.
 67. Seidl K, Leimer N, Palheiros Marques M, Furrer A, Senn G, Holzmann-Burgel A, Matt U, Zinkernagel AS. USA300 methicillin-resistant *Staphylococcus aureus* in Zurich, Switzerland between 2001 and 2013. *Int J Med Microbiol.* 2014;304(8):1118-22.
 68. Seifert D, Di Giallonardo F, Metzner KJ, Gunthard HF, Beerenwinkel N. A framework for inferring fitness landscapes of patient-derived viruses using quasispecies theory. *Genetics.* 2014;Journal:[ePub ahead of Print].
 69. Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, Bouchez O, Gabriel C, Izopet J, Kessler HH, Stelzl E, Di Giallonardo F, Schlapbach R, Radonic A, Paredes R, Recordon-Pinson P, Sakwa J, St John EP, Schmitz-Agheguian GG, Metzner KJ, Daumer MP, Group HIVA. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. *J Virol Methods.* 2014;204:31-7.
 70. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte AdA, Phillips AN, Sabin CA, Lundgren JD. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *The Lancet.* 2014;384(9939):241-8.

71. Stern M, Hirsch H, Cusini A, van Delden C, Manuel O, Meylan P, Boggian K, Mueller NJ, Dickenmann M, SwissTransplantCohortStudy. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. *Transplantation*. 2014;98(9):1013-8.
72. Taveira A, Ponroy N, Mueller NJ, Millard AL. Entry of human cytomegalovirus into porcine endothelial cells depends on both the cellular vascular origin and the viral strain. *Xenotransplantation*. 2014;21(4):324-40.
73. Ueda S, Uchiyama S, Azzi T, Gysin C, Berger C, Bernasconi M, Harabuchi Y, Zinkernagel AS, Nadal D. Oropharyngeal group A streptococcal colonization disrupts latent Epstein-Barr virus infection. *J Infect Dis*. 2014;209(2):255-64.
74. von Braun A, Braun DL, Kamarachev J, Günthard HF. New Onset of Kaposi Sarcoma in a Human Immunodeficiency Virus-1-Infected Homosexual Man, Despite Early Antiretroviral Treatment, Sustained Viral Suppression, and Immune Restoration. *Open Forum Infectious Diseases*. 2014;1(1).
75. Wang Q, Young J, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Fehr J, Bucher HC, Battegay M, SwissHIVCohortStudy. Virologic and immunologic responses in treatment-naïve patients to ritonavir-boosted atazanavir or efavirenz with a common backbone. *HIV Clin Trials*. 2014;15(3):92-103.
76. Weber R, Huber M, Battegay M, Stahelin C, Castro Batanjer E, Calmy A, Bregenzer A, Bernasconi E, Schoeni-Affolter F, Ledergerber B, SwissHIVCohortStudy. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. *HIV Med*. 2014.
77. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD. 2014 Update of the drug resistance mutations in HIV-1. *Top Antivir Med*. 2014;22(3):642-50.
78. Xiao YL, Abrahamowicz M, Moodie EEM, Weber R, Young J. Flexible Marginal Structural Models for Estimating the Cumulative Effect of a Time-Dependent Treatment on the Hazard: Reassessing the Cardiovascular Risks of Didanosine Treatment in the Swiss HIV Cohort Study. *Journal of the American Statistical Association*. 2014;109(506):455-64.
79. Young J, Wang Q, Fux CA, Bernasconi E, Furrer H, Vernazza P, Calmy A, Cavassini M, Weber R, Battegay M, Bucher HC, SwissHIVCohortStudy. The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. *HIV Med*. 2014;15(8):505-10.
80. Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, Allegranzi B, Magiorakos AP, Pittet D, group ftsrae-bgooohipcSs. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. *Lancet Infect Dis*. 2014.

81. Zingg W, Huttner BD, Sax H, Pittet D. Assessing the burden of healthcare-associated infections through prevalence studies: what is the best method? *Infect Control Hosp Epidemiol.* 2014;35(6):674-84.
82. Zoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard GD, Schmiedel S, Drexler JF, Campbell NK, Taka N, Awasom C, Metzner KJ, van Lunzen J, Feldt T. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon. *J Antimicrob Chemother.* 2014.

Case Reports

1. Flammer Anikpeh Y, Grimm F, Lindenblatt N, Zinkernagel A. It isn't always caviar. *BMJ Case Rep.* 2014;2014.
2. Kaiser P, Maggio EM, Pfammatter T, Misselwitz B, Flury S, Schneider PM, Dutkowski P, Breitenstein S, Mullhaupt B, Clavien PA, Mueller NJ. Histopathological evidence of invasive gastric mucormycosis after transarterial chemoembolization and liver transplantation. *Infection.* 2014;42(4):779-83.
3. Naf F, Enzler-Tschudy A, Kuster SP, Uhlig I, Steffen T. Abdominal actinomycosis mimicking a malignant neoplasm. *Surg Infect (Larchmt).* 2014;15(4):462-3.

Übersichtsartikel / Reviews

1. Battegay M, Haerry DH, Fehr J, Staehelin C, Wandeler G, Elzi L. [Psychosocial aspects on the treatment of HIV-infection]. *Ther Umsch.* 2014;71(8):509-13.
2. Braun DL, Nemeth J, Gunthard HF. [Don't miss the primary HIV-infection]. *Ther Umsch.* 2014;71(8):469-74.
3. Durisch N, Mueller N. Norovirus-Gastroenteritis. *Der Gastroenterologe.* 2014;9(4):360-5.
4. Fehr J, Scharer V, Hirzel C, Rauch A. [Hepatitis B and C in HIV coinfection]. *Ther Umsch.* 2014;71(8):490-6.
5. Fluckiger M, Andreisek G, Hasse B. [Acute spondylodiscitis]. *Praxis (Bern 1994).* 2014;103(19):1103-13.
6. Frohlich MR, Meier MT, Staudacher D, Schubert M. [Prevention of ventilator associated pneumonia at the University of Zurich intensive care unit. Ventilator associated pneumonia - an intensive problem]. *Krankenpfl Soins Infirm.* 2014;107(9):30-1.
7. Gunthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA, International Antiviral Society USAP. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA.* 2014;312(4):410-25.

8. Hasse B, Bernasconi E, Furrer H, Eyer MM, Kovari H. [HIV-associated non-AIDS conditions]. *Ther Umsch.* 2014;71(8):483-9.
9. Huser MC, Meindl-Fridez C, Zinkernagel AS. [Gram positive toxic shock syndrome]. *Praxis (Bern 1994).* 2014;103(22):1293-9; quiz 300-1.
10. Landolt L, Kovari H. Erythema migrans. *Praxis (Bern 1994).* 2014;103(25):1491-8. 11. Ledergerber B, Battegay M. [Epidemiology of HIV]. *Ther Umsch.* 2014;71(8):437-41.
12. Metzner KJ. [Pathogenesis of HIV-1]. *Ther Umsch.* 2014;71(8):443-50.
13. Nadal D, Arlettaz R, Berger C. [Vertical HIV infection is preventable but remains challenging]. *Ther Umsch.* 2014;71(8):503-8.
14. Pfisterer D, Georgi A, Gunthard H. [Acute HIV infection]. *Praxis (Bern 1994).* 2014;103(5):247-51; quiz 52-3.
15. Scharer V, Bruggmann P, Mullhaupt B, Fehr J. [Treatment of hepatitis C – an imminent revolution]. *Praxis (Bern 1994).* 2014;103(19):1123-31.
16. Scharer V, Hafner R, Ciurea A, Henning L, Somoskovi A, Weber R, Fehr J. [Limitations of medicine: diagnosis and therapy of <<inflammatory>> back pain]. *Praxis (Bern 1994).* 2014;103(6):337-40.
17. Schreiber P, Fauchere I, Wyss C. [Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome]. *Praxis (Bern 1994).* 2014;103(18):1049-58.
18. Schupbach J, Berger C, Boni J, Speck RF. [Diagnosing HIV in Switzerland]. *Ther Umsch.* 2014;71(8):451-60.
19. Sommerstein R, Von Braun A, Weber R, Fehr J. Pneumonie beim Erwachsenen. Teil 2: Die im Spital erworbene Pneumonie. *Swiss Medical Forum.* 2014;14(33):590-3.
20. Staehelin C, Elzi L, Weber R, Furrer H. [Treatment and prevention of opportunistic infections]. *Ther Umsch.* 2014;71(8):475-82.
21. Stolaroff-Pepin A, Speck RF, Vernazza P. [Prevention of HIV and other sexually transmitted infections (STI)]. *Ther Umsch.* 2014;71(8):515-23.
22. Toutous Trelu L, Oertle D, Itin P, Scheidegger C, Stoeckle M, Schmid P, Bernasconi E, Cavassini M, Boffi El Amari E, Kahlert C, Vernazza P, Fehr J, Calmy A, Low N, Martinetti Lucchini G, Tarr PE. Gonorrhoe: neue Empfehlungen zu Diagnostik und Behandlung. *Swiss Medical Forum.* 2014.
23. von Braun A, Furrer H, Battegay M, Calmy A, Cavassini M, Vernazza P, Bernasconi E, Weber R, Gunthard HF. [Antiretroviral therapy]. *Ther Umsch.* 2014;71(8):461-8.

24. Von Braun A, Sommerstein R, Weber R, Fehr J. Pneumonie beim Erwachsenen. Teil 1: Die ambulant erworbene Pneumonie. Swiss Medical Forum. 2014;14(31-32):560-5.
25. Weber R, Gunthard HF. [HIV infection today]. Ther Umsch. 2014;71(8):433-5.
26. Wolfensberger A, Huber M, Choschzick M, Mueller NJ. Abdominale Tuberkulose. Der Gastroenterologe. 2014;9(4):372-7.
27. Zweifel VB, Berger C, Nadal D, Grawe C. [HIV and pregnancy]. Ther Umsch. 2014;71(8):498-502.

Buchkapitel

1. Speck RF. Anti-retroviral Treatment Testing in HIV-infected Humanized Mice. In: Poluektova L, Garcia-Martinez V, Koyanagi Y, Manz MG, Tager A, editors. Humanized Mice for HIV Research: Springer; 2014.
2. Uçkay I, Sax H, Hoffmeyer P, Lew D, Pittet D. Severe soft-tissue infections. In: Bersten A, Soni N, editors. Oh's intensive care manual. London: Elsevier; 2014. p. 733.

Andere Arbeiten

1. Conen A, Wang Q, Fehr J. Authors reply to the letter to the editor by Carrieri et al. HIV and alcohol - the ongoing debate. J Acquir Immune Defic Syndr 2014.

Habilitationen

1. Hasse B. Klinischer Langzeitverlauf der HIV Infektion: Resultate der Schweizerischen HIV Kohortenstudie. Erteilung der Venia legendi für das Gebiet Infektiologie. Habilitation an der Medizinischen Fakultät der Universität Zürich, 2014.

Dissertationen

1. Bütikofer S. Prevalence and risk factors of late presentation for HIV diagnosis and care in a tertiary referral centre in Switzerland. Dissertation an der Universität Zurich (Medizinische Fakultät) 2014. Leitung: Prof. Dr. Bruno Ledergerber.
2. Di Giallonardo F. HIV-1 quasispecies analysis by next-generation sequencing to determine the mechanisms of viral evolution. Dissertation an der Universität Zurich (MNF) 2014. Leitung: Prof. Dr. Karin Metzner
3. Ponroy N. Anti-Cytomegalovirus Activity of Statins: Cellular and Molecular Mechanism. Dissertation an der Universität Zurich (MNF) 2014. Leitung: Prof. Dr. David Nadal und Prof. Dr. Nicolas Müller
4. Taveira A. Comparison of human cytomegalovirus entry mechanisms into porcine and human endothelial cells. Dissertation an der Universität Zurich (MNF) 2014. Leitung: Prof. Dr. Nicolas Müller

5. Vongrad V. Identification of mechanisms controlling and maintaining HIV-1 latency in vivo. Dissertation an der Universität Zurich (MNF) 2014. Leitung: Prof. Dr. Karin Metzner

Masterarbeiten

1. Clack L. Human Factors Informed Infection Control Signage. Masterarbeit an der University of Nottingham (School of Mechanical, Materials and Manufacturing Engineering), 2014. Leitung: Dr. Sue Cobb
2. Fuchs C. Klinische Relevanz von aus Schwämmen zur topischen Unterdruckwundbehandlung isolierten Bakterien bei Gefäßprotheseninfekten. Masterarbeit an der Universität Zürich (Medizinische Fakultät), 2014. Leitung: PD Dr. Barbara Hasse
3. Scotoni M. Machen unsere Hände was sie wollen – oder was wir wollen? Masterarbeit an der Universität Zürich (Medizinische Fakultät), 2014. Leitung: PD Dr. Hugo Sax
4. Leemann M. Mechanisms and consequences of Staphylococcus aureus endothelial cell interactions. Masterarbeit an der Universität Zürich (MNF), 2014. Leitung: PD Dr. Annelies Zinkernagel